Oramed Pharmaceuticals Analyst Ratings
Oramed Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/12/2023 | — | Canaccord Genuity | Downgrades | Buy → Hold | |
| 05/16/2022 | 178.04% | Aegis Capital | $35 → $30 | Maintains | Buy |
| 02/18/2022 | 85.36% | Cantor Fitzgerald | → $20 | Initiates Coverage On | → Overweight |
| 11/30/2021 | 196.57% | HC Wainwright & Co. | $17 → $32 | Maintains | Buy |
| 11/29/2021 | 196.57% | HC Wainwright & Co. | $17 → $32 | Maintains | Buy |
| 11/02/2021 | 224.37% | Aegis Capital | $20 → $35 | Maintains | Buy |
| 07/29/2021 | 178.04% | Canaccord Genuity | $27 → $30 | Maintains | Buy |
| 06/08/2021 | 85.36% | Aegis Capital | $12 → $20 | Maintains | Buy |
| 04/20/2021 | 150.23% | Canaccord Genuity | → $27 | Initiates Coverage On | → Buy |
| 02/09/2021 | 113.16% | National Securities Corporation | → $23 | Initiates Coverage On | → Buy |
| 01/27/2021 | 11.21% | Aegis Capital | $6 → $12 | Maintains | Buy |
| 07/13/2020 | 57.55% | HC Wainwright & Co. | $16 → $17 | Reiterates | → Buy |
| 06/22/2020 | 48.29% | HC Wainwright & Co. | $20 → $16 | Maintains | Buy |
| 09/11/2019 | -35.13% | Ladenburg Thalmann | → $7 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变化 | 上一页/当前额定值 |
|---|---|---|---|---|---|
| 01/12/2023 | — | Canaccord Genu | 降级 | 买入 → 持有 | |
| 05/16/2022 | 178.04% | 宙斯盾资本 | 35 美元 → 30 美元 | 维护 | 买 |
| 02/18/2022 | 85.36% | 坎托·菲茨杰拉德 | → 20 美元 | 开启覆盖范围 | → 超重 |
| 11/30/2021 | 196.57% | HC Wainwright & Co. | 17 美元 → 32 美元 | 维护 | 买 |
| 11/29/2021 | 196.57% | HC Wainwright & Co. | 17 美元 → 32 美元 | 维护 | 买 |
| 11/02/2021 | 224.37% | 宙斯盾资本 | 20 美元 → 35 美元 | 维护 | 买 |
| 07/29/2021 | 178.04% | Canaccord Genu | 27 美元 → 30 美元 | 维护 | 买 |
| 06/08/2021 | 85.36% | 宙斯盾资本 | 12 美元 → 20 美元 | 维护 | 买 |
| 04/20/2021 | 150.23% | Canaccord Genu | → 27 美元 | 开启覆盖范围 | → 购买 |
| 02/09/2021 | 113.16% | 国家证券公司 | → 23 美元 | 开启覆盖范围 | → 购买 |
| 01/27/2021 | 11.21% | 宙斯盾资本 | 6 美元 → 12 美元 | 维护 | 买 |
| 07/13/2020 | 57.55% | HC Wainwright & Co. | 16 美元 → 17 美元 | 重申 | → 购买 |
| 06/22/2020 | 48.29% | HC Wainwright & Co. | 20 美元 → 16 美元 | 维护 | 买 |
| 09/11/2019 | -35.13% | 拉登堡塔尔曼 | → 7 美元 | 开启覆盖范围 | → 购买 |
What is the target price for Oramed Pharmaceuticals (ORMP)?
Oramed Pharmicals（ORMP）的目标价格是多少？
The latest price target for Oramed Pharmaceuticals (NASDAQ: ORMP) was reported by Cantor Fitzgerald on February 18, 2022. The analyst firm set a price target for $20.00 expecting ORMP to rise to within 12 months (a possible 85.36% upside). 2 analyst firms have reported ratings in the last year.
坎托·菲茨杰拉德于2022年2月18日公布了Oramed Pharmicals（纳斯达克股票代码：ORMP）的最新目标股价。这家分析公司将目标价设定为20.00美元，预计ORMP将在12个月内升至12个月（可能上涨85.36％）。去年，有两家分析公司公布了评级。
What is the most recent analyst rating for Oramed Pharmaceuticals (ORMP)?
Oramed Pharmicals（ORMP）的最新分析师评级是多少？
The latest analyst rating for Oramed Pharmaceuticals (NASDAQ: ORMP) was provided by Cantor Fitzgerald, and Oramed Pharmaceuticals initiated their overweight rating.
Oramed Pharmicals（纳斯达克股票代码：ORMP）的最新分析师评级由坎托·菲茨杰拉德提供，Oramed Pharmicals开始了增持评级。
When is the next analyst rating going to be posted or updated for Oramed Pharmaceuticals (ORMP)?
Oramed Pharmicals（ORMP）的下一个分析师评级将在何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Oramed Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Oramed Pharmaceuticals was filed on February 18, 2022 so you should expect the next rating to be made available sometime around February 18, 2023.
分析师在进行了广泛的研究后得出了股票评级，包括浏览公开财务报表，与Oramed Pharmicals的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月这样做一次，因此每家公司每年应该获得4次评级。Oramed Pharmicals的最新评级是在2022年2月18日提交的，因此您应该预计下一个评级将在2023年2月18日左右公布。
Is the Analyst Rating Oramed Pharmaceuticals (ORMP) correct?
分析师评级 Oramed Pharmicals（ORMP）是否正确？
While ratings are subjective and will change, the latest Oramed Pharmaceuticals (ORMP) rating was a initiated with a price target of $0.00 to $20.00. The current price Oramed Pharmaceuticals (ORMP) is trading at is $10.79, which is within the analyst's predicted range.
虽然评级是主观的，而且会发生变化，但最新的Oramed Pharmicals（ORMP）评级最初的目标价为0.00美元至20.00美元。Oramed Pharmicals（ORMP）目前的交易价格为10.79美元，在分析师的预测区间内。